
    
      Twenty eyes will be randomized will receive 3 consecutive monthly intravitreal 2.0 mg/0.5mg
      (3:1 ratio) Ranibizumab injection with the first injection occuring at Day 0 and second and
      third injection occuring at month 1 and month 2 respectively. Retreatment with intravitreal
      Ranibizumab or other therapies will be at the investigators discretion but guidelines for
      recommended retreatment.
    
  